David Ludvigson - Jun 4, 2021 Form 3 Insider Report for Boston Therapeutics, Inc. (NNMX)

Role
CEO and President, Director
Signature
/s/ David Ludvigson
Stock symbol
NNMX
Transactions as of
Jun 4, 2021
Transactions value $
$0
Form type
3
Date filed
6/29/2021, 08:46 PM
Next filing
Dec 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NNMX Common Stock, $0.0001 par value per share 0 Jun 4, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NNMX Series C Preferred Stock Jun 4, 2021 Common Stock, $0.0001 par value per share 58.3M Direct F1
holding NNMX Warrants Jun 4, 2021 Common Stock, $0.0001 par value per share 6.5M $0.00 Direct F2
holding NNMX Restricted Stock Units Jun 4, 2021 Common Stock, $0.0001 par value per share 182M $0.00 Direct F3
holding NNMX Incentive Stock Options Jun 4, 2021 Common Stock, $0.0001 par value per share 7.22M $0.00 Direct F4
holding NNMX Incentive Stock Options Jun 4, 2021 Common Stock, $0.0001 par value per share 96.7M $0.00 Direct F4
holding NNMX Incentive Stock Options Jun 4, 2021 Common Stock, $0.0001 par value per share 14.9M $0.00 Direct F4
holding NNMX Incentive Stock Options Jun 4, 2021 Common Stock, $0.0001 par value per share 14.7M $0.00 Direct F4
holding NNMX Incentive Stock Options Jun 4, 2021 Common Stock, $0.0001 par value per share 22.1M $0.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series C Preferred Stock has a stated value of $1.00 per share and is convertible into shares of common stock at a conversation rate of 6,066.044596 shares of common stock for each share of Series C Preferred Stock. The shares of Series C Preferred Stock are automatically converted upon the filing of an amendment to the Company's certificate of incorporation implementing a reverse stock split.
F2 The shares underlying the warrants and the RSU may not be exercised until the implementation of a reverse stock split.
F3 RSUs vesting over 2 years
F4 Previously issued ISO stock options vested and unvested